Updates
MEDICAL AFFAIRS DIGEST
1ST NOVEMBER 2024 EDITION
- Research That Reflects Reality
- Super models: A framework to optimise R&D success with AI
- Deep faith: Transforming the clinical trials landscape with the brave application of AI
MEDICAL AFFAIRS DIGEST
2ND OCTOBER 2024 EDITION
- Top Trends Shaping the Pharmaceutical Industry in 2024
- AI and new technologies: How the pharmaceutical industry is reinventing itself to meet ever more urgent needs
- Deepening perspectives: How social media is driving our understanding of HCP sentiment
MEDICAL AFFAIRS DIGEST
1ST OCTOBER 2024 EDITION
- Four Key Strategies for Optimizing Your Medical Congress Strategy
- The Cynic in the Clinic: Overcoming HCP Distrust Using Behavioral Science
- The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients
MEDICAL AFFAIRS DIGEST
2ND SEPTEMBER 2024 EDITION
- Artificial Intelligence in Medical Affairs: A New Paradigm with Novel Opportunities
- The Power of Patient Stories in Medical Communications
- Personalizing Pharma: Overcoming Challenges to Drive Digital Customer Engagement
MEDICAL AFFAIRS DIGEST
1ST SEPTEMBER 2024 EDITION
- Harnessing Digital Innovations for Sustainable Continuous Medical Education (CME) Across Borders
- Making more medicines that matter
- As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
MEDICAL AFFAIRS DIGEST
1ST AUGUST 2024 EDITION
- Patient-Centric Approach in Pharma: The Shift Towards Patient Engagement and Feedback
- The Art of Being an Impactful MSL
- How Can General Managers Best Leverage Medical Affairs Now and in the Future?
MEDICAL AFFAIRS DIGEST
1ST JULY 2024 EDITION
- The Role of Medical Affairs in Bridging Clinical Trial Access for All Patients
- Amplifying the Patient’s Voice in Oncology Early-Phase Clinical Trials: Solutions to Burdens and Barriers
- Data-Driven Development: How Real-World Data and AI Are Transforming Clinical Trials
MEDICAL AFFAIRS DIGEST
1ST JUNE 2024 EDITION
- A maturity model for the scientific review of clinical trial designs and their informativeness
- NIH scientists develop AI tool to predict how cancer patients will respond to immunotherapy
- Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers
MEDICAL AFFAIRS DIGEST
2ND JUNE 2024 EDITION
- The Role of Medical Affairs in Promoting Environmental Sustainability: Lessons Learned
- Behind the powerful computations, AI’s role in pharma is still beset by challenges
- Welcome to Unified Customer Experience: The Next Level of Omnichannel
MEDICAL AFFAIRS DIGEST
1ND MAY 2024 EDITION
- Fostering Global Collaboration in Healthcare for Sustainable Solutions
- THINK TANK: AI’s impact on Pharma
- Women want to participate in clinical trials. Lack of flexibility is still a problem
MEDICAL AFFAIRS DIGEST
2ND MAY 2024 EDITION
- Pioneering the Path Pre- and Post-Launch Strategies
- Currency of Information
- Enhancing Patient Profiles to Support Personalized Care
MEDICAL AFFAIRS DIGEST
1ST APRIL 2024 EDITION
- Accelerating Time to Treatment in Rare Disease
- The Impact of AI in Healthcare
- Fine-tuning Analytical Development Strategies For Every Phase
MEDICAL AFFAIRS DIGEST
2ND APRIL 2024 EDITION
- The Crucial Role of Understanding Disease Ecosystems in R&D and Medical Affairs
- It’s Time We Got the Most Out of Medical Affairs Data
- Redefining the Role of Medical Affairs Professionals as Innovators and Leaders in Industry-Led Medical Education
MEDICAL AFFAIRS DIGEST
1ST MARCH 2024 EDITION
- Rare Disease Day: Enhancing clinical trial success in rare diseases
- Increasing patient and public involvement in clinical research
- Decentralized Clinical Trials Outlook
MEDICAL AFFAIRS DIGEST
2ND MARCH 2024 EDITION
- The Importance of Medical Affairs in Preparing a Patient Journey Map
- 8 Tactics to Increase HCP Engagement in 2024
- From Development to Commercialization: Transforming Medical Insights Into Action
MEDICAL AFFAIRS DIGEST
2ND JANUARY 2024 EDITION
- Building Innovative Sustainability Programs: Quantify and Reduce Your Meetings’ Carbon Emissions
- 3 Innovative Ways to Empower Patients with Interactive and Educational Ads
- How to make 2024 a banner year for biopharma, despite the headwinds
MEDICAL AFFAIRS DIGEST
2ND FEBRUARY 2024 EDITION
- Accelerating clinical trials to improve biopharma R&D productivity
- The Latest Trend in Global Pharma: Transforming MSLs into ISL role. How to be Ready for That?
- Generative AI in the pharmaceutical industry: Moving from hype to reality
Medical Affairs Digest
1st January 2024 Edition
- How artificial intelligence can power clinical development
- The Impact of Small Companies on Global Health: A Closer Look at Virtual Initiatives
- The Impact of Suboptimal Cancer Drug Trials on Patient Health
MEDICAL AFFAIRS DIGEST
1ST FEBRUARY 2024 EDITION
- Modern KOL Connections: Engaging with Thought Leaders in the Age of AI
- Patient Engagement Needs More Benefit Analysis, Fewer Theoretical Conversations
- Key Opinion Leaders Engagement
Medical Affairs Digest
1st December 2023 Edition
- How to Manage Objections in KOL Interactions to Enhance Insights and Elevate Relationship Development
- The Value of MSLs in Clinical Trials
- The Impact of AI on Medical Affairs
Medical Affairs Digest
1st November 2023 Edition
- A vision for medical affairs 2030: Five priorities for patient impact
- The Evolving Role of Medical Science Liaisons (MSLs): How the Role of MSLs is Changing in Response to Technological Advancements and Evolving Healthcare Needs
- A Shift in Medical Affairs Amid the Challenge of Data Management and Rise of AI
Medical Affairs Digest
2nd November 2023 Edition
- Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed?
- Driving Diversity and Inclusion in Cancer Drug Development – Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges
- 3 Reasons People Don’t Enroll In Clinical Trials — And How To Overcome Them
Medical Affairs Digest
1st October 2023 Edition
- Do humans have a place in pharma’s AI future?
- Beyond Participation: Evaluating the Role of Patients in Designing Oncology Clinical Trials
- Elderly exclusion: Clinical trials still fall short enrolling older adults
Medical Affairs Digest
2nd October 2023 Edition
- A vision for medical affairs 2030: Five priorities for patient impact
- Advancing patient-centricity in Medical Affairs: A survey of patients and patient organizations
- How Can Pharmaceutical Companies Meet Drug Launch Expectations
Medical Affairs Digest
1st September 2023 Edition
- WHO proposes best practices for clinical trials
- The Critical Role Of Medical Affairs In Discovery Through Phase 2 Clinical Trials
- A checklist for unlocking the promise of AI in clinical trials
Medical Affairs Digest
2nd September 2023 Edition
- From Insights to Outcomes: Leveraging Technology to Measure Medical Impact
- The Future of Pharma: Top 5 trends impacting the pharmaceutical industry in 2023
- When “K” and “D” Overlap in Engaging with Opinion Leaders
Medical Affairs Digest
July 2023 Edition
- The FDA wants to modernize clinical trials
- Empowering Clinical Trials: The Role of Generative AI in Accelerating Pharmaceutical R&D
- Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment
Medical Affairs Digest
August 2023 Edition
- Global Survey Reveals How MSLs Are Maximizing KOL Engagement During Medical Conferences
- An In-Depth Dive into the Significance of Modern Communication Skills for Health Care Professionals
- Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Medical Affairs Digest
1st June 2023 Edition
- Factors Affecting Success of New Drug Clinical Trials
- Equitable Access to Clinical Trials: How Do We Achieve It?
- It’s a match! Connecting patients to clinical trials with AI
Medical Affairs Digest
2nd June 2023 Edition
- Advancing patient-centricity in Medical Affairs: A survey of patients and patient organizations
- How biopharma executives fight burnout
- Asynchronous digital medicine: How digital health technology is moving the care paradigm
Medical Affairs Digest
1st May 2023 Edition
- Three Ways AI Can Accelerate Innovations in Clinical Research
- What Role Could ChatGPT Have in Clinical Trials? A Bigger One Than You Might Think
- Don’t Wait—Uncover the Clinical Endpoints that Will Matter to Payers and HCPs
Medical Affairs Digest
2nd May 2023 Edition
- Patient influencers are here to stay — where are the regulations?
- Using Business Acumen to Level-up as an MSL
- Life sciences technology insights: Scaling a product and platform model
Medical Affairs Digest
1st April 2023 Edition
- Women in the healthcare industry: An update
- Everyone says they’re patient-centric, but have they really walked the walk?
- Top 3 Ways ChatGPT Will Change Medical Affairs
Medical Affairs Digest
2nd April 2023 Edition
- Deep Dive into the Powerful Impact of Artificial Intelligence on Medical Affairs Function
- AI for medtech commercial growth: Five missteps to avoid
- AI is about to remake the pharmaceutical industry
Medical Affairs Digest
1st March 2023 Edition
- Celebrate women in science — today, and every day
- Five ways biopharma companies can navigate the deal landscape
- AI Transforming Real-World Clinical Development
Medical Affairs Digest
2nd March 2023 Edition
- Evolution of the MSL Function: 2030
- Find, Engage, and Partner with the Right Digital Opinion Leaders
- Being KOL-Centric: More Meaningful Expert Engagement
Medical Affairs Digest
1st February 2023 Edition
- Top ten observations from 2022 in life sciences digital and analytics
- Using Patient Perspectives to Inform Better Clinical Trial Design and Conduct: Current Trends and Future Directions
- The next generation of evidence-based medicine
Medical Affairs Digest
2nd February 2023 Edition
- Do You Hear Me? When HCPs Want Their Opinions Heard
- How to effectively engage KOLs in a virtual format
- 4 Reasons Pharma’s Organizational Structures Are Not Built for Digital Transformation
Medical Affairs Digest
1st January 2023 Edition
- The digital therapeutics revolution is happening and Big Pharma is buying in — with caution
- Resilience in life sciences: Emerging stronger from the downturn
- Trendspotting: Hybrid and Decentralized Clinical Trials, Patient-Centricity, and Increased Remote Patient Monitoring in 2023
Medical Affairs Digest
2nd January 2023 Edition
- What’s keeping pharma leaders up at night
- Revealing the true value of medical affairs
- The Digital Era is Expanding the Scope and Impact for Medical Affairs
Medical Affairs Digest
October 2022 Edition
- Agents of change: How the Gen Z medical science liaison will transform healthcare
- How to run an interactive MSLs training in a virtual format for continued efficiency and excellence
- Reevaluating “Difficult” Doctor-Patient Relationships
Medical Affairs Digest
December 2022 Edition
- The future of biotech: AI-driven drug discovery
- Medical affairs in a digital-first world: Benefits and challenges
- From insight to action in Medical Affairs
Medical Affairs Digest
November 2022 1st Edition
- Emerging from disruption: The future of pharma operations strategy
- Digital Strategies For Optimizing Clinical Development
- The design and evaluation of hybrid controlled trials that leverage external data and randomization
Medical Affairs Digest
November 2022 2nd Edition
- How AI could revolutionize drug discovery
- The role of Medical Affairs in cutting CO2 emissions
- Driving the Evolution of Medical Affairs and MSLs
Medical Affairs Digest
September 2022 1st Edition
- Patient involvement in clinical trials
- What Makes an Oncology Clinical Trial Site Stand Out from the Competition?
- When Will We Solve the Patient Engagement Dilemma?
Medical Affairs Digest
September 2022 2nd Edition
- Developing pharmaceutical launch leaders and company-wide capabilities at scale
- How to build a medical affairs go-to-market framework for the future
- How digital transformation is driving action in healthcare
Medical Affairs Digest
July 2022 Edition
- Opinion: Many Clinical Trials Fail to Navigate the Literature
- Clinical trial trends and market changes to watch out for in 2022-23
- Myths about diversity in clinical trials reduce return on investment for industry
Medical Affairs Digest
August 2022 Edition
- Developing pharmaceutical launch leadeanand company-wide capabilities at scale
- Achieving Effective KOL Engagement and Intelligence Gathering During Medical Conferences
- Evolving Trends: Continuing Medical Education (CME) In The Digital Space
Medical Affairs Digest
May 2022 Edition
- Three challenges to global collaboration in pharma and how to overcome them
- Medical Affairs Teams need to Learn to Engage with Digital Opinion Leaders
- From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting
Medical Affairs Digest
June 2022 Edition
- A look ahead: How medical affairs may evolve over the next five years
- Digital Opinion Leaders (DOLs): Who are they and how can Pharma engage them?
- How digital helps a life sciences leader move at light speed
Medical Affairs Digest
April 2022 1st Edition
- Patient Influencers: The Next Frontier in Direct-to-Consumer Pharmaceutical Marketing
- Scientific Share of Voice as KPI for Medical Activities – Key Success Factors
- Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core
Medical Affairs Digest
April 2022 2nd Edition
- Decentralized Clinical Trials: A Revolution Improving Safety, Efficacy, and Speed
- International Clinical Trials: how the war in Ukraine affects the Clinical Trial market and patients and what kind of amendments to legislation might be needed in the future
- How can real-world evidence help medical affairs professionals?
Medical Affairs Digest
March 2022 1st Edition
- Digital interactions with HCPs — moving from Webinars to a more interactive communication tool: a new normal for Pharma Industry
- What role for virtual engagement in 2022?
- Digital transformation in the pharma industry post-Covid
Medical Affairs Digest
March 2022 2nd Edition
- Clinical Trial Trens- what will 2022 bring?
- Prediction of treatment outcome in clinical trials under a personalized medicine perspective
- Clinical Data Management: Past, Present and Future
Medical Affairs Digest
February 2022 1st Edition
- The Future of Clinical Trials is Here Today
- 11 clinical trials that will shape medicine in 2022
- Are you ready? EU’s Clinical Trials Regulation and portal goes live 31 January
Medical Affairs Digest
February 2022 2nd Edition
- Overcoming The Challenges of Outsourcing Rare Disease Trials
- EMA launches new centre to gather real-world health data for drug regulation
- How the Pandemic Shaped the Next Wave of Health Tech Innovation
Medical Affairs Digest
December 2021
- Move over KOLs, there’s a new influencer in town. Meet the digital opinion leaders taking over online
- The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
- COVID Vaccine Trials Offer Lessons for Improving Clinical Trial Diversity
Medical Affairs Digest
January 2022
- A new operating model for pharma: How the pandemic has influenced priorities
- Discovering the unique power of DOLs – are you harnessing the power of pharma’s new educators?
- Are You Leveraging KOLs For Biopharma Market Access As Much As You Could Be?
Medical Affairs Digest
October 2021
- Medical Affairs Digitization
- Clinical Trial Trends: 18 Months of Faster Tech Adoption, Real World Data, Increased Collaboration
- How To Diversify Trials: Recruitment Protocols, Other Approaches
Medical Affairs Digest
November 2021
- The New Hybrid KOL Engagement Model
- AI: Rewriting the Clinical Development Handbook
- Advances In Precision Medicine And Artificial Intelligence Are Set To Transform Cancer Treatment
Medical Affairs Digest
September 2021 1st Edition
- Building Trust in Real-World Evidence
- Diversity & Inclusion in Clinical Trials: What Role Can Medical Affairs Play?
- The Time is Right to Disrupt Clinical Cancer Trials and Accelerate Innovation
Medical Affairs Digest
September 2021 2nd Edition
- Aspiration vs Actuality – Assessing the progress of digital excellence in Medical Affairs
- How Medical Affairs Can Contribute to Successful Drug Launch
- Getting strategic about new-product submissions in the pharma industry
Medical Affairs Digest
July 2021 1st Edition
- No place like home? Stepping up the decentralization of clinical trials
- Preparing for the Next Normal: Transformation in the Role of Medical Affairs Following the COVID-19 Pandemic
- Digital Technology-Based Telemedicine for the COVID-19 Pandemic
Medical Affairs Digest
August 2021 1st Edition
- A Decade in Review: Changes in Temporal and Regional Interest in the Medical Science Liaison Role
- Medical Affairs – The Future Strategists Of The Pharma Industry?
- Virtual relationships with KOLs: Insights from the COVID-19 scenario
Medical Affairs Digest
June 2021 1st Edition
- The COVID-19 pandemic and new clinical trial activations
- Envisioning A Transformed Clinical Trials Enterprise For 2030
- Managing clinical trials during COVID-19: experience from a clinical research facility
Medical Affairs Digest
June 2021 2nd Edition
- How Gamification Can Help Pharma Companies Play to Win
- MSL Jobs in a Post-Pandemic World
- Mapping KOL relationships
Medical Affairs Digest
May 2021 1st Edition
- Big innovation shift to small pharma? Rookies grab lead in annual poll—and look to stay put
- Virtual advisory boards: what pharma learned in 2020 and new trends for the Post-COVID era
- What’s ahead for biotech: Another wave or low tide?
Medical Affairs Digest
May 2021 2nd Edition
- The essentials of healthcare innovation
- Cancer and COVID-19 vaccines: a complex global picture
- How the medtech industry can capture value from digital health
Medical Affairs Digest
April 2021 1st Edition
- Who are Medical Science Liaisons and MSL Managers?
- Position Yourself for Success – The Medical Science Liaison in the New World
- What Does 2021 Hold for Biopharma? Part 2: COVID-19 Shock Waves and Silver Linings
Medical Affairs Digest
April 2021 2nd Edition
- Patient engagement: Why the public should be part of the conversation around AI in healthcare
- COVID-19 and cancer: 1 year on
- A call to action: Opportunities and challenges for CGTs in Europe
Medical Affairs Digest
March 2021 1st Edition
- Operations can launch the next blockbuster in pharma
- COVID’s impact on cancer therapeutics: clinical trial and treatment disruptions
- Clinical Trial Strategy: How to Ensure Quality
Medical Affairs Digest
March 2021 2nd Edition
- Developing Medical Affairs Leaders Who Create the Future/li>
- Clinical Research During the COVID-19 Pandemic: The Role of Virtual Visits and Digital Approaches
- Professional and personal impact of the COVID-19 pandemic restrictions on non-COVID-related clinical research
Medical Affairs Digest
February 2021 1st Edition
- American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
- How Medical Affairs might help in patient recruitment for Clinical Trials: a closer look at the new role of an Investigator Science Liaison
- 4 Cornerstones of Pharma Medical Affairs
Medical Affairs Digest
February 2021 2nd Edition
- Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape/li>
- Pharma’s role in maintaining cancer mortality progress during COVID-19
- A call to action: Opportunities and challenges for Cell and Gene Therapies in Europe
Medical Affairs Digest
January 2021 1st Edition
- Ready for launch: Reshaping pharma’s strategy in the next normal
- KOLs reveal how they prefer to engage with MSLs during the COVID-19 pandemic
- Healthtech in the fast lane: What is fuelling investor excitement?
Medical Affairs Digest
January 2021 2nd Edition
- MSLs in the age of COVID: KOL perceptions of MSL virtual engagements
- Adding value to KOL VIRTUAL ENGAGEMENT from the MSL Excellence perspective
- Biopharma 2020: A landmark year and a reset for the future
Medical Affairs Digest
December 2020 1st Edition
- Medical affairs post COVID 19: Are we ready to take the baton?
- Association of the COVID-19 outbreak with patient willingness to enrol in Cancer Clinical Trials
- Will patient-centric sampling become the norm for clinical trials after COVID-19?
Medical Affairs Digest
December 2020 2nd Edition
- COVID-19 Opens a New Era for Real-World Evidence in Pharma
- Digital agility and customer-centricity – imperatives for Medical Affairs in a post-COVID world
- It will change everything’: DeepMind’s AI makes gigantic leap in solving protein structures
Medical Affairs Digest
November 2020 1st Edition
- Will Artificial Intelligence revolutionize clinical trials?
- The potential of real-world data
- US Food and Drug Administration Support for Oncology Drug Development During COVID-19
Medical Affairs Digest
November 2020 2nd Edition
- Reimagining how life sciences work will be done in the next normal
- Clinical trials in the post Brexit Europe
- The Salesforce of the Future
- Healthcare innovation: Building on gains made through the crisis
Medical Affairs Digest
October 2020 1st Edition
- How Artificial Intelligence can be used to innovate clinical trial design
- Impact of COVID-19 on oncology clinical trials
- AACR report: COVID struck as science was making unprecedented impact on cancer
Medical Affairs Digest
October 2020 2nd Edition
- Digital Revolution in Healthcare and Strategic Role of Medical Affairs Amidst Covid-19 Outbreak
- The future of Medical Congresses
- Medical Affairs Improves Patient Outcomes Through External Medical Education
Medical Affairs Digest
September 2020 1st Edition
- Playing to win in oncology: Key capabilities for success
- COVID-19 and readjusting clinical trials
- Clinical trials in Oncology: challenges with patient recruitment and time to change the status quo
Medical Affairs Digest
September 2020 2nd Edition
- KOLs reveal how they prefer to engage with MSLs during the COVID-19 pandemic
- Future Perspectives on the MSL Role After the COVID-19 Pandemic
- How to Focus Virtual Meetings for Medical Affairs
